In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers.
Ryan Flinn
Advertisement
Articles by Ryan Flinn
Advertisement
Latest Updated Articles
From CAR T’s “Wait List Mortality” to “Tethering” Bispecific Antibodies, Oncologists Navigate Time-Sensitive Sequencing in Multiple MyelomaPublished: December 19th 2023 | Updated:
Miles Matter: The Geographic Disparity That Impacts Access to CAR T TherapyPublished: October 13th 2024 | Updated:
Banner Year for Bispecifics as Therapies Advance Into the Community SettingPublished: February 19th 2025 | Updated:
As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?Published: November 20th 2024 | Updated:
Table Multiple Myeloma Trials November 2024Published: November 1st 2024 | Updated:
Wave of Antibody-Drug Conjugates Poised to Change Treatment Paradigms Across Multiple CancersPublished: May 29th 2024 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Major Bleeding Prevention, Treatment Requires Vigilance in Patients With ET
2
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
3
MRD-Triggered Anti-CD20 Therapy Effective in High-Risk CLL
4
Executive Order on Homelessness Includes Several Policy Shifts: Katherine Koh, MD, MSc
5
